for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tcr2 Therapeutics Inc

TCRR.O

Latest Trade

7.01USD

Change

0.14(+2.04%)

Volume

43,921

Today's Range

6.71

 - 

7.08

52 Week Range

5.84

 - 

21.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.87
Open
6.71
Volume
43,921
3M AVG Volume
1.72
Today's High
7.08
Today's Low
6.71
52 Week High
21.45
52 Week Low
5.84
Shares Out (MIL)
24.08
Market Cap (MIL)
168.77
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

TCR² Therapeutics Reports Q3 Loss Per Share Of $0.58

TCR² Therapeutics Reports Q2 Loss Per Share $0.46

TCR2 Therapeutics Qtrly Loss Per Share $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tcr2 Therapeutics Inc

TCR2 Therapeutics, Inc. is an immunotherapy company, which is developing novel T cell therapies for patients suffering from cancer. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The Company has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The Company has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310.

Contact Info

100 Binney St

CAMBRIDGE, MA

02142-1096

United States

+1.617.9495200

http://www.tcr2.com/

Executive Leadership

Ansbert K. Gadicke

Chairman of the Board

Garry E. Menzel

President, Chief Executive Officer, Director

Ian Somaiya

Chief Financial Officer

Robert Hofmeister

Chief Scientific Officer

Stephen Turkowiak

Vice President - Finance

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-98.530

2019

-4.620

2020(E)

-2.540
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-33.41
Return on Equity (TTM)
-31.95

Latest News

Latest News

BRIEF-TCR2 Therapeutics Files For Mixed Shelf Offering Of Up To $300 Mln

* TCR2 THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $300 MILLION - SEC FILING Source text: (http://bit.ly/2uZYhnU) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up